Newton, MA, United States of America

Leonardo Vidal Riella

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: The General Hospital Corporation, Visterra, Inc.. Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Leonardo Vidal Riella: Innovator in Interleukin-2 Research

Introduction

Leonardo Vidal Riella is a notable inventor based in Newton, MA (US). He has made significant contributions to the field of immunology, particularly through his work on interleukin-2 agents. His innovative approaches have the potential to impact the treatment and prevention of various disorders.

Latest Patents

Leonardo holds 1 patent for his invention titled "Methods of using interleukin-2 agents." This patent discloses IL-2 agents that comprise IL-2 variants, along with methods, compositions, and uses thereof. The IL-2 agents described can be utilized to treat and/or prevent a range of disorders and conditions, showcasing the therapeutic potential of his research.

Career Highlights

Throughout his career, Leonardo has worked with prominent organizations, including Visterra, Inc. and The General Hospital Corporation. His experience in these institutions has allowed him to collaborate with leading experts in the field and further his research endeavors.

Collaborations

Leonardo has collaborated with notable colleagues such as Scott Moore Carlson and Gregory Babcock. These partnerships have contributed to the advancement of his research and the development of innovative solutions in immunology.

Conclusion

Leonardo Vidal Riella's work in the field of interleukin-2 research exemplifies the impact of innovation in medicine. His contributions have the potential to lead to significant advancements in the treatment of various health conditions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…